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THE POTENTIAL IMPACT OF CHELATION THERAPY (CT) ON
THE QUALITY OF LIFE (QOL) OF PATIENTS WITH IRON
OVERLOAD (IO)
Abetz L1, Jones P2, Baladi JF2
1Mapi Values, Macclesﬁeld, Cheshire, UK; 2Novartis Pharmaceutical
Corporation, East Hanover, PA, USA
OBJECTIVES: Repeated blood transfusions can result in IO and
lead to life-threatening complications in patients with sickle cell
disease (SCD), thallasaemia (TLA) or myelodysplastic syndrome
(MDS). The most common IO CT, Desferal (DFO), requires infu-
sions of 8–12 hours, 5–7 days per week, potentially limiting QoL
and inhibiting adherence. METHODS: A literature review (539
abstracts; 130 articles), analysis of four IO patient transcripts
(one MDS, one SCDA, two TLA) and interviews with three IO
experts were conducted to assess the potential impact of CT on
patients’ lives. RESULTS: Results suggested the signiﬁcant neg-
ative impact of CT with DFO on patient QoL, particularly social
life, self-image, intimate relationships, emotional well-being,
pain and sleep, though very few published studies (15) measured
this impact with validated QoL instruments. No IO or CT-spe-
ciﬁc QoL instruments were found. Published articles and
patient/clinician input suggested a need for easier, efﬁcacious and
safe oral IO treatments, given the impact of current CT on QoL
inhibits adherence. CONCLUSION: Limited empirical studies
assessed the impact of CT or IO on QoL, though all reviewed
articles stated that CT’s QoL impact is signiﬁcant and would
improve with oral therapy. However, the impacted QoL domains
may differ by age, condition, and how long CT has been used.
It is recommended to continue both the qualitative and the quan-
titative study of QoL in chelated patients in patients with MDS,
SCD, and TLA using validated instruments in order to further
our understanding of the issues and improve patient’s quality of
life.
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HOW PATIENTS WITH HAEMOPHILIA ARE SATISFIED WITH
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OBJECTIVES: Treatment of patients with haemophilia, a 
congenital bleeding disorder, treated with repeated infusions of
clotting factor concentrates, requires a substantial amount of
economical and human resources and therefore it is mandatory
to investigate treatment satisfaction of haemophilic patients.
Purpose of this study was to evaluate patients’ experience of dif-
ferent treatment regimens and to validate the newly developed
haemophilia-speciﬁc treatment satisfaction scale for adults
(Hemo-SatA) in the COCHE Study (Cost of Care of Hemophilia
Study). METHODS: 233 adult haemophilia patients without
inhibitors from 23 Italian Haemophilia Centers were enrolled in
the naturalistic, multicenter, longitudinal COCHE Study. Treat-
ment satisfaction was assessed with the Hemo-SatA, which con-
sists of 34 items pertaining to 6 domains (ease & convenience,
efﬁcacy, burden, specialist, centre, general). RESULTS: Mean age
of patients was 37 years. Around one-third of the patients
received prophylactic treatment (n = 75) and most of them were
treated with recombinant products (58.8%). In general patients
were satisﬁed with their treatment. Patients were mostly unsat-
isﬁed in the dimensions “ease & convenience” and “efﬁcacy”;
42% worried about the risk of inhibitors associated with their
medication and 14% were unsatisﬁed with the number of infu-
sions that are needed to stop a bleeding. Signiﬁcant differences
in treatment satisfaction (Hemo-SatA) were found for socio-
demographic data concerning marital status and age groups
(“burden”); separated persons were more unsatisﬁed with their
treatment (“specialist”, “general satisfaction”, “Total Hemo-
Sat”).Signiﬁcant differences were found as well for clinical data
concerning ‘treatment type’, ‘type of haemophilia’ and ‘target
joints’; patients with more than 1 target joint were more un-
satisﬁed (“efﬁcacy”). Psychometric characteristics of the pilot
testing of the Hemo-SatA could be conﬁrmed in the COCHE
Study. CONCLUSIONS: Results could conﬁrm that treatment
satisfaction is an important outcome criterion in the treatment
of patients with chronic diseases. Hemo-SatA proved to be a
valid and reliable instrument assessing.
NEUROLOGICAL DISORDERS
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EXTERNAL VALIDATION OF THE PROBABILISTIC MARKOV
MODEL ESTIMATING THE COST EFFECTIVENESS OF
MEMANTINE VERSUS STANDARD CARE IN ALZHEIMER
DISEASE FROM A UK PERSPECTIVE
Guilhaume C1, Rive B2, Francois C1, Livingston G3, Katona C4
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A Markov model was developed to estimate the cost effective-
ness of memantine compared with no pharmacological treatment
in British AD patients with MMSE £14 over a 2-year period. It
simulated a patient’s progression through series of health stages
combining different level of severity, dependency and setting of
care. Transition probabilities for the model were computed on
the basis of the data from the LASER-AD cohort (London and
the Southeast Region Alzheimer’s Disease) over six months, and
were then extrapolated using the Markov assumption to simu-
late the long-term course of disease. Since then the LASER-AD
has been extended and now 18 months data follow up are avail-
able. OBJECTIVE: To validate the model externally by compar-
ing the results extrapolated in the model with those observed in
the LASER-AD cohort at 18 months. METHOD: A Markov
cohort analysis was conducted on the model in order to compute
the percentages of patients in the different health stages at all
cycles using the distribution at baseline of the LASER-AD. The
analysis was conducted on the “standard care” treatment strat-
egy only, and was stopped at the third cycle (18 months). Per-
centages from the model were compared with those obtained
from the LASER-AD study after having observed 95 patients
with a baseline MMSE £14. RESULTS: Based on model analy-
ses, after 18 months 84.5% of patients are severe, 87.8% are
dependent and 71.5% are institutionalized (versus respectively
83.8%, 90.3% and 73.3% in the LASER-AD). The difference
between the two estimates is greatest for mortality (respectively
40.6% versus 31.6%). CONCLUSION: It is rare to have the
opportunity to validate a pharmacoeconomic model externally.
These analyses show very similar estimates of the disease course
between the memantine UK pharmacoeconomic model and the
‘real’ long-term data from the LASER-AD cohort. This strength-
ens the modeling approach used.
PNL2
COST-EFFECTIVENESS OF ADDING MEMANTINE TREATMENT
TO PATIENTS RECEIVING STABILISED DOSES OF DONEPEZIL
IN THE UK
Guilhaume C1, Rive B2, Cochran J1
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OBJECTIVES: Assess the cost-effectiveness in a UK setting 
of providing memantine treatment to moderate to severe
